(14)	Segment Information and Concentrations of Risk

We operate under two reportable segments, Merge Healthcare and Merge DNA. Our Merge Healthcare operating group, which represents about 83% of our total revenue in 2013, markets, sells and implements interoperability, imaging and clinical solutions to healthcare providers. Our Merge DNA (Data and Analytics) operating group represents the remaining revenue and focuses on data capture software for clinical trials and other solutions.

We evaluate the performance of these operating groups based on their respective revenues and operating income, which exclude public company costs, certain corporate costs (amortization expense that is not specific to a segment), net interest expense and income taxes.

The following tables present operating group financial information for the periods indicated.

	Year ended December 31, 2013
	Healthcare		DNA		Total
Net sales:
Software and other	$	57,371	$	21,204	$	78,575
Professional Services		28,290		15,540		43,830
Maintenance and EDI		107,220		2,042		109,262
Total net sales		192,881		38,786		231,667
Expenses		171,838		35,094		206,932
Segment income	$	21,043	$	3,692		24,735

Net corporate/other expenses (1)						60,829
Loss before income taxes					$	(36,094	)

	Year ended December 31, 2012
	Healthcare		DNA			Total
Net sales:
Software and other	$	78,941	$	15,525		$	94,466
Professional Services		27,552		13,426			40,978
Maintenance and EDI		110,894		2,566			113,460
Total net sales		217,387		31,517			248,904
Expenses		192,408		33,315			225,723
Segment income (loss)	$	24,979	$	(1,798	)		23,181

Net corporate/other expenses (1)							47,910
Loss before income taxes						$	(24,729	)

	Year ended December 31, 2011
	Healthcare		DNA		Total
Net sales:
Software and other	$	76,947	$	4,001	$	80,948
Professional Services		23,437		18,468		41,905
Maintenance and EDI		109,562		13		109,575
Total net sales		209,946		22,482		232,428
Expenses		166,898		20,406		187,304
Segment income	$	43,048	$	2,076		45,124

Net corporate/other expenses (1)						46,990
Loss before income taxes					$	(1,866	)

(1)

Net corporate/other expenses include public company costs, corporate administration expenses, amortization expense

	Healthcare		DNA		Corporate/ Other			Consolidated
Depreciation and amortization

Year ended December 31, 2013	$	13,522	$	3,949	$	49		$	17,520
Restructuring and Other One Time Charges

Year ended December 31, 2013	$	2,886	$	405	$	565		$	3,856

Assets as of December 31, 2013	$	333,789	$	42,894	$	5,728		$	382,411

	Healthcare		DNA		Corporate/ Other			Consolidated
Depreciation and amortization

Year ended December 31, 2012	$	16,049	$	4,187	$	59		$	20,295
Restructuring and Other One Time Charges

Year ended December 31, 2012	$	333	$	497	$	-		$	830

Assets as of December 31, 2012	$	412,841	$	33,207	$	(9,195	)	$	436,853

	Healthcare		DNA		Corporate/ Other			Consolidated
Depreciation and amortization

Year ended December 31, 2011	$	19,311	$	2,165	$	732		$	22,208
Restructuring and Other One Time Charges

Year ended December 31, 2011	$	1,216	$	-	$	-		$	1,216

Assets as of December 31, 2011	$	354,442	$	47,722	$	48,223		$	450,387

Foreign sales account for approximately 7%, 6%, and 9% of our net sales in 2013, 2012, and 2011, respectively, and sales in foreign currency represented approximately 2%, 3%, and 2%, respectively, of our net sales in 2013, 2012 and 2011.

The following tables present certain geographic information, based on location of customer:

	Net Sales for the Years Ended December 31,
	2013		2012		2011
United States of America	$	216,560	$	232,848	$	211,907
Europe		7,566		8,687		8,767
Japan		2,061		2,190		5,312
Korea		1,105		1,018		1,449
Canada		1,718		1,707		1,598
Other		2,657		2,454		3,395
Total Net Sales	$	231,667	$	248,904	$	232,428

	Long Lived Assets
	2013		2012		2011
United States of America	$	4,184	$	4,316	$	3,866
Canada		487		569		520
Europe		68		79		3
Other		-		-		2
Total	$	4,739	$	4,964	$	4,391